Drug Interactions

Foundations of Drug Interaction Recognition in Pharmacy Practice

Drug interactions occur when the effect of one drug is altered by the presence of another substance—whether a medication, food, herb, or supplement. As a pharmacy technician, you are on the front line of identifying  potential interactions during prescription processing, data entry, and patient counseling. Recognizing common interaction mechanisms and high-risk drugs is essential for exam success and patient safety.^[1]

Why it matters on the PTCE & in practice: Interactions account for a significant portion of medication errors and preventable adverse events. The PTCE routinely tests your ability to identify interacting drug pairs, understand the role of drug-metabolizing enzymes (e.g., CYP450), and apply pharmacy procedures to prevent harmful combinations.^[2]

Core Terminology for Drug Interaction Mechanisms

• Drug–drug interaction (DDI): A change in a drug’s effect due to another drug. Can be additive, synergistic, or antagonistic.^[3]
• Drug–food interaction: When food alters drug absorption or metabolism (e.g., grapefruit juice inhibits CYP3A4).^[4]
• Drug–herb/supplement interaction: Commonly seen with St. John’s wort (induces CYP3A4) and ginseng (affects warfarin).^[5]
• Pharmacokinetic interactions: Affect absorption, distribution, metabolism, or excretion (ADME). Most tested are metabolism-based (e.g., CYP450 inhibition/induction).
• Pharmacodynamic interactions: Drugs act at the same receptor or physiologic system, leading to additive or opposing effects (e.g., alcohol + benzodiazepines → CNS depression).^[3]
• Therapeutic duplication: Two drugs with the same effect used together (e.g., two NSAIDs), often unintentional during OTC + Rx combinations.

Metabolic Pathways and Clinical Screening Protocols

1. Cytochrome P450 (CYP450) System

• The CYP450 enzyme family (mainly in the liver) metabolizes ~75% of all medications.^[6]
• Inhibitors block enzyme activity → ↑ drug level → risk of toxicity. Example: clarithromycin inhibits CYP3A4, raising simvastatin levels.
• Inducers increase enzyme synthesis → ↓ drug level → loss of efficacy. Example: rifampin induces CYP3A4, reducing oral contraceptive effectiveness.
• High-yield CYP substrates to know: warfarin (CYP2C9), statins (CYP3A4), clopidogrel (CYP2C19), codeine (CYP2D6 to active morphine).

2. P-glycoprotein (P-gp) Interactions

• P-gp is an efflux transporter that pumps drugs out of cells (e.g., in the gut, brain).
• Inhibitors (verapamil, amiodarone) can increase oral absorption of digoxin, leading to toxicity.
• Inducers (rifampin) decrease digoxin bioavailability.

3. Screening and Prevention Workflow

1. Data entry: Enter all Rx, OTC, and supplement products into the pharmacy system.
2. Prospective drug utilization review (DUR): The pharmacist reviews alerts generated by software for potential interactions.
3. Severity assessment: Categorized as contraindicated, significant (monitor/modify therapy), or minor.
4. Patient counseling: Advise on timing adjustments (e.g., separate doses by 2 hours for fluoroquinolones + calcium/iron).

Pharmacodynamic and Pharmacokinetic Interaction Patterns

• Additive effect: 1+1=2. Example: alcohol + benzodiazepines → severe CNS depression.
• Synergistic effect: 1+1>2. Example: TMP/SMX + warfarin → increased INR due to both protein displacement and enzyme inhibition.
• Antagonistic effect: One drug reduces another’s effect. Example: naloxone blocks opioid receptors, reversing morphine.
• Altered absorption: Tetracyclines chelate with calcium, iron, magnesium—absorption ↓ significantly if taken together.
• Altered electrolyte balance: Diuretics + digoxin → hypokalemia increases digoxin toxicity risk.

Profile Review and Interaction Flagging Procedures

Pharmacy technicians do not diagnose interactions, but you must evaluate patient profiles and communicate concerns. For the exam:

• Always check for duplicate therapy (e.g., two ACE inhibitors).
• Review the patient’s allergy list and conditions (e.g., renal impairment can magnify interaction risk).
• Use the prescription fill history to identify new additions or dose changes that could trigger an interaction.

Preventive Strategies and Patient Counseling Responsibilities

Technician’s role in preventing & managing interactions:

• Alert the pharmacist whenever a soft-ware flag or an unusual prescription combination appears.
• Separate administration times for interacting drugs when possible (e.g., levothyroxine and calcium—take 4 hours apart).
• Counsel patients to avoid grapefruit juice if they take statins or certain calcium-channel blockers.
• Document OTC and herbal product use on patient profiles to help the pharmacist identify interactions.

High-Risk Drug Combinations and Contraindications

• Warfarin + NSAIDs: Increased bleeding risk → monitor INR, advise acetaminophen instead for pain.
• ACE inhibitors + potassium supplements: Risk of hyperkalemia → avoid concurrent use without monitoring.
• Methotrexate + NSAIDs: Reduced renal clearance of methotrexate → severe myelosuppression.
• MAO inhibitors + SSRIs (or tyramine-rich foods): Serotonin syndrome or hypertensive crisis.
• Contraindicated combos: Statin + gemfibrozil (increased myopathy/rhabdomyolysis risk per FDA).^[7]

PTCE-Focused Interaction Patterns and Mnemonics

• Memorize the “grapefruit juice” rule: It inhibits CYP3A4, raising levels of many statins, CCBs, and immunosuppressants.
• The “CYP” mnemonic: 3A4 = most common (HIV drugs, statins, CCBs, azoles); 2D6 = codeine, antidepressants; 2C9 = warfarin, NSAIDs.
• Always identify the mechanism: Is it pharmacokinetic (ADME) or pharmacodynamic (receptor/tissue level)?
• Know the classic pairs tested: Warfarin + antibiotics (↑ INR), digoxin + amiodarone (↑ digoxin level), clopidogrel + omeprazole (↓ clopidogrel activation).
• Interactions involving OTCs: Antacids reduce absorption of most drugs (take 2 hours apart); calcium supplements block tetracyclines.
• Remember the pharmacist will make the final clinical decision—your role is to identify and bring the interaction to their attention.

References & Sources

1. American Society of Health-System Pharmacists (ASHP). Pharmacy Technician: Foundations and Practices. 3rd ed. ASHP; 2021. Accessed March 2025. https://www.abebooks.com/9781585280902/ASHP-MANUAL-PHARMACY-TECHNICIANS-3E-1585280909/plp
2. Pharmacy Technician Certification Board (PTCB). Pharmacy Technician Certification Examination (PTCE) Blueprint. 2023. https://www.ptcb.org/
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. McGraw-Hill; 2021. Chapter 4: Drug Interactions. https://accessmedicine.mhmedical.com/content.aspx?bookid=2988§ionid=250593594
4. U.S. Food and Drug Administration (FDA). "Grapefruit Juice and Some Drugs." Updated February 2023. https://www.fda.gov/consumers/consumer-updates/grapefruit-juice-and-some-drugs-dont-mix
5. National Center for Complementary and Integrative Health (NCCIH). "Herb-Drug Interactions: What You Should Know." Updated 2021. https://www.nccih.nih.gov/health/
6. Flockhart DA, Oesterheld JR, et al. Cytochrome P450-mediated drug interactions. Med Clin North Am. 2020;104(2):345–360. https://doi.org/10.1016/j.mcna.2019.11.002
7. U.S. Food and Drug Administration (FDA). "FDA Drug Safety Communication: Interactions between certain statins and gemfibrozil increase risk for muscle injury." 2020. https://www.fda.gov/drugs/drug-safety-and-availability/